Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Advanced Breast Cancer

Trial Profile

A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Advanced Breast Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab (Primary) ; Capecitabine; Docetaxel; Eribulin; Gemcitabine; Paclitaxel; Trastuzumab; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms PRECIOUS
  • Most Recent Events

    • 06 Jun 2023 Results of updated overall survival at the median follow-up of 27.4 months presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 01 Sep 2022 Status changed from active, no longer recruiting to completed.
    • 01 Sep 2022 Primary endpoint (Progression-free survival (assessed by investigators)) has been met, according to Results published in the Cancer Science.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top